Olesya Grinenko, MD
Payments from drug & device makers
What this record shows
DIXI Medical USA Corp accounts for 86.4% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2022 at $2,707 and has fallen 92.6% since, to $201 in 2025.
Across 17 payments — averaging $184.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- DIXI Medical USA Corp$3K
- SK Life Science, Inc.$122
- AbbVie$114
- Biogen$80
- Livanova USA, Inc.$48
- UCB, Inc.$23
- plus $38 from 2 others
What the payments were for
- Travel & lodging$1,61952%
- Food & beverage$1,51348%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| DIXI Medical USA Corp | 3 | $2,707 |
| SK Life Science, Inc. | 1 | $122 |
| AbbVie | 5 | $114 |
| Biogen | 3 | $80 |
| Livanova USA, Inc. | 2 | $48 |
| UCB, Inc. | 1 | $23 |
| Catalyst Pharmaceuticals, Inc. | 1 | $20 |
| Supernus Pharmaceuticals, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Cenobamate$122
How this compares
$3,132 in reported general payments places this provider in the 75th percentile of 132 neurology providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nurtec OdtRimegepant Sulfate | 22 | $25,077 |
| Aimovig AutoinjectorErenumab-Aooe | 20 | $14,545 |
| Dalfampridine ErDalfampridine | 15 | $12,113 |
| Dimethyl Fumarate | 14 | $9,843 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 220 | $6,759 |
| Levetiracetam | 122 | $4,813 |
| Lacosamide | 29 | $4,278 |
| Rivastigmine | 13 | $3,451 |
| Entacapone | 12 | $3,081 |
| Memantine Hcl | 49 | $2,118 |
| Primidone | 77 | $2,017 |
| Propranolol Hcl ErPropranolol Hcl | 45 | $1,814 |
| Donepezil Hcl | 240 | $1,604 |
| Topiramate | 46 | $1,200 |
| Gabapentin | 79 | $1,086 |
Paid to pharmacies, not to this prescriber.
Other neurology in Ames
- Anu BawejaAmes$6K
- David MooreAmes$5K
- Semira RamicAmes$1K
- Bruce HughesDes Moines$1.8M
- Michael JacobyDes Moines$243K
- Lynn RankinDes Moines$181K
- Winthrop RiskCedar Rapids$136K
- Wendy ZadehDes Moines$134K
- Paul BabikianDes Moines$107K
- Scott GeislerCedar Rapids$87K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.